| Patents for C07K 14 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof (291,526) |
|---|
| 09/19/2002 | WO2002072600A2 Monoclonal antibodies to the clfa protein and method of use in treating or preventing infections |
| 09/19/2002 | WO2002072596A1 Steap-related protein |
| 09/19/2002 | WO2002072140A2 Mhc-i-restricted presentation of hiv-1 virion antigens without viral replication. application to the stimulation of ctl and vaccination in vivo; analysis of vaccinating composition in vitro |
| 09/19/2002 | WO2002072138A1 Methods and materials relating to fibulin-like polypeptides and polynucleotides |
| 09/19/2002 | WO2002072134A1 Remedies for arthritis deformans and remedies for rheumatoid arthritis |
| 09/19/2002 | WO2002072130A1 Method of preventing adhesions by apoptosis of adhesion peritoneal cells |
| 09/19/2002 | WO2002072126A2 Invention relating to hcv diseases |
| 09/19/2002 | WO2002072079A2 Modulators of the ank-pyrophosphate channel for use in osteoporosis therapy |
| 09/19/2002 | WO2002072036A2 Compositions and methods comprising west nile virus polypeptides |
| 09/19/2002 | WO2002072030A2 High affinity integrin polypeptides and uses thereof |
| 09/19/2002 | WO2002072027A2 Oncolytic rna replicons |
| 09/19/2002 | WO2002072024A2 Transgenic proteins from multi-gene systems, methods, compositions, uses and the like relating thereto |
| 09/19/2002 | WO2002072023A2 Production of high levels of transgenic factor viii with engineered stability, and its therapeutic uses |
| 09/19/2002 | WO2002072017A2 Method of drug target validation |
| 09/19/2002 | WO2002072015A2 M cell directed vaccines |
| 09/19/2002 | WO2002072005A2 Linear y-carboxyglutamate rich conotoxins |
| 09/19/2002 | WO2002071927A2 Diagnosis and treatment of skeletal degeneration conditions |
| 09/19/2002 | WO2002071843A1 Recombinant adeno-assocaited virus-mediated gene transfer via retroductal infusion of virions |
| 09/19/2002 | WO2002055549A3 Systems for expression of heterologous proteins in m. capsulatus |
| 09/19/2002 | WO2002055532A3 Variant growth hormone molecules conjugated with macromolecular compounds |
| 09/19/2002 | WO2002053181A8 Enterohemorragic escherichia coli vaccine |
| 09/19/2002 | WO2002050292A3 Modulation of plant cyclin-dependent kinase inhibitor activity |
| 09/19/2002 | WO2002050119A3 Method for modulating the binding activity of a novel icam-3 binding receptor on sinusoidal endothelial cells in liver and lymph nodes |
| 09/19/2002 | WO2002048391A3 Dormancy - induced mycobacterium proteins |
| 09/19/2002 | WO2002042311A3 Biotin derivatives, methods for making same and uses thereof as vectors |
| 09/19/2002 | WO2002036620A9 Ets-transcription factor related compound specific promoter and transactivators thereof |
| 09/19/2002 | WO2002036172A3 Rotavirus enterotoxin nsp4 and methods of using same |
| 09/19/2002 | WO2002036154A9 Procollagen (iii) propeptides and related substances for treating fibrotic diseases |
| 09/19/2002 | WO2002033119A9 Mutations in the ferroportin 1 gene associated with hereditary haemochromatosis |
| 09/19/2002 | WO2002033079A3 Human g-protein coupled receptor and uses thereof |
| 09/19/2002 | WO2002032940A3 Osteopontin-coated surfaces and methods of use |
| 09/19/2002 | WO2002030876A3 Cyclic carboxylic acids as integrin antagonists |
| 09/19/2002 | WO2002026765A3 Haplotypes of the muc1 gene |
| 09/19/2002 | WO2002022871A3 Polymorphic bone morphogenetic protein 2 |
| 09/19/2002 | WO2002022825A9 The c. albicans tec1 gene (catec1) and the coded tec1p protein |
| 09/19/2002 | WO2002014350A3 Peptide and peptide mimetic derivatives with integrin inhibitor properties ii |
| 09/19/2002 | WO2002010382A9 Trp8, trp9 and trp10, markers for cancer |
| 09/19/2002 | WO2002010379A3 Modified cea and uses thereof |
| 09/19/2002 | WO2002010362A9 Methods of controlling gene expression and gene silencing |
| 09/19/2002 | WO2002010192A3 Somatostatin analogues |
| 09/19/2002 | WO2002006464A3 Large scale expression and purification of recombinant proteins |
| 09/19/2002 | WO2002004487A3 Method for producing and using novel human defensins as biologically active proteins for treating infections and other illnesses |
| 09/19/2002 | WO2002002765A3 Chimeric promoters for controlling expression in smooth muscle cells |
| 09/19/2002 | WO2002002610A3 Secretion and trafficking molecules |
| 09/19/2002 | WO2001096370A9 Cryptosporidium parvum antigens, antibodies thereto and diagnostic and therapeutic compositions thereof |
| 09/19/2002 | WO2001092525A3 Compositions and methods for the therapy and diagnosis of lung cancer |
| 09/19/2002 | WO2001092299A9 Adenovirus particles with mutagenized fiber proteins |
| 09/19/2002 | WO2001090188A9 Receptor-based interaction trap |
| 09/19/2002 | WO2001090185A3 Pt32 sperm protein, sperm c-yes, oocyte cytoplasmic c-yes, and uses thereof |
| 09/19/2002 | WO2001090162A9 Crystal structure data of cystalysin and use thereof for the design and preparation of inhibitor molecules |
| 09/19/2002 | WO2001088127A3 Regulation of human follicle stimulating hormone-like g protein-coupled receptor |
| 09/19/2002 | WO2001085769A3 Structure of g-protein (rgs4) and methods of identifying agonists and antagonists using same |
| 09/19/2002 | WO2001085208A8 Molecular antigen arrays and vaccines |
| 09/19/2002 | WO2001083783A3 In vivo loading of mhc |
| 09/19/2002 | WO2001083514A3 Nucleic acids encoding a regulator of a g protein signaling, rgs18, and uses thereof |
| 09/19/2002 | WO2001081379A3 Compounds and methods for treatment and diagnosis of chlamydial infection |
| 09/19/2002 | WO2001077291A3 Polynucleotides encoding novel secreted proteins |
| 09/19/2002 | WO2001066740A3 Compositions and methods for the treatment of immune related diseases |
| 09/19/2002 | WO2001064949A3 Diagnostics and therapeutics for glaucoma |
| 09/19/2002 | WO2001051518A3 Nucleic acids encoding human semaphorin proteins and use thereof |
| 09/19/2002 | WO2001046406A3 New qtl's on chromosomes x, 2, 6 and 7 of pigs |
| 09/19/2002 | WO2001036630A9 Triggering receptor involved in natural cytotoxicity mediated by human natural killer cells, and antibodies that identify the same |
| 09/19/2002 | WO2001030843A9 Ligand activated transcriptional regulator proteins |
| 09/19/2002 | WO2001007483A9 Prognosis and therapy of malignant diseases by antibodies which bind phosphorylated met protein |
| 09/19/2002 | WO2000071578A9 New polypeptides and their use for the rescue of fusion defective virus or retrovirus glycoproteins |
| 09/19/2002 | WO1999060109A3 Soybean gene promoters |
| 09/19/2002 | US20020133852 Nucleotide sequences for use as marker tools in sequence and genome analysis |
| 09/19/2002 | US20020133851 Method for enhancement of naturally occurring cytoplasmic male sterility and for restoration of male fertility and uses thereof in hybrid crop production |
| 09/19/2002 | US20020133850 Melon promoters for expression of transgenes in plants |
| 09/19/2002 | US20020133848 Identification and characterization of an anthocyanin mutant (ANT1) in tomato |
| 09/19/2002 | US20020133847 Plant proteins |
| 09/19/2002 | US20020133846 Method for protecting plants |
| 09/19/2002 | US20020133845 Barstar gene |
| 09/19/2002 | US20020133844 Animal model for use in the treatment of cell proliferative disorders |
| 09/19/2002 | US20020133843 Expression vector for generating animal models for use in the treatment of epilepsy, depression and hyperactivity |
| 09/19/2002 | US20020133841 Expression vector for generating animal models for use in the treatment of epilepsy, tension and pain disorders |
| 09/19/2002 | US20020133840 Expression vector for generating animal model for use in the treatment of propagation, psychological and nervous system disorders |
| 09/19/2002 | US20020133839 Expression vector for generating animal model for use in the treatment of cardiovascular and nervous system disorders |
| 09/19/2002 | US20020133836 Methods to identify swine genetically resistant to F18 E. coli associated diseases |
| 09/19/2002 | US20020133834 Test and model for alzheimer's disease |
| 09/19/2002 | US20020133832 Model systems for neuordegenerative and cardiovascular disorders |
| 09/19/2002 | US20020133001 Therapeutic agents and methods of use thereof for treating an amyloidogenic disease |
| 09/19/2002 | US20020133000 Neuronal protein for use in inducing sleep and for treatment of sleep disorders |
| 09/19/2002 | US20020132999 Novel human P24 vesicle proteins |
| 09/19/2002 | US20020132998 Nucleotide sequences coding channel protein for use in human therapeutics and diagnostic, cosmetics, drug screening and the development of nutrients |
| 09/19/2002 | US20020132996 Secretory protein-48 |
| 09/19/2002 | US20020132994 Nucleotide sequences coding polypeptide for use in the treatment and prevention of microorganismal infections |
| 09/19/2002 | US20020132991 Purifying anionic target proteins from a sample; obtain mixed protein samples, incubate with reversibility binding substrate, purify anionic target proteins |
| 09/19/2002 | US20020132985 Removing multivalent ions from protein; obtain solution containing protein, adjust hydrogen ion concentration, diafilter solution, recover retentate |
| 09/19/2002 | US20020132981 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 09/19/2002 | US20020132979 Monoclonal antibody for use in the diagnosis, prevention and treatment of tumors |
| 09/19/2002 | US20020132978 VEGF-modulated genes and methods employing them |
| 09/19/2002 | US20020132977 Polypeptide for use in the diagnosis and treatment of cancer |
| 09/19/2002 | US20020132974 Material composed of amino acid sequences for use in diagnosis and treatment of nervous system and brain disorders |
| 09/19/2002 | US20020132973 Peptide parathyroid hormone analogs |
| 09/19/2002 | US20020132789 Especially for rickettsial pathogen selected from the group consisting of Rickettsia spp., Ehrlichia spp., Anaplasma spp., and Cowdria |
| 09/19/2002 | US20020132786 Inhibitors of Apoptosis protein used to modulate apoptosis or to identify modulators of apoptosis as well as in therapeutic uses. |
| 09/19/2002 | US20020132775 Human potassium channel 1 and 2 proteins |
| 09/19/2002 | US20020132774 Neuropilin antagonist that binds neuropilin and has VEGF antagonist activity as determined by the human umbilical vein endothelial cell proliferation assay using VEGF165; treatment of metastatic cancer, and angiogenic diseases. |
| 09/19/2002 | US20020132769 Comprising a soluble adenoviral receptor domain, a trimerization domain, and a targeting ligand domain; using molecule to treat a disease, such as cancer, with adenoviral gene therapy; side effect reduction |